- Home
- CLLS vs ALDX Comparison
CLLS vs ALDX Comparison
Compare CLLS & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- ALDX
- Stock Information
- Founded
- CLLS 1999
- ALDX 2004
- Country
- CLLS France
- ALDX United States
- Employees
- CLLS N/A
- ALDX N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- ALDX Health Care
- Exchange
- CLLS Nasdaq
- ALDX Nasdaq
- Market Cap
- CLLS 144.4M
- ALDX 133.7M
- IPO Year
- CLLS 2007
- ALDX 2014
- Fundamental
- Price
- CLLS $1.49
- ALDX $2.12
- Analyst Decision
- CLLS Buy
- ALDX Strong Buy
- Analyst Count
- CLLS 3
- ALDX 2
- Target Price
- CLLS $6.67
- ALDX $9.50
- AVG Volume (30 Days)
- CLLS 46.6K
- ALDX 1.1M
- Earning Date
- CLLS 05-12-2025
- ALDX 07-31-2025
- Dividend Yield
- CLLS N/A
- ALDX N/A
- EPS Growth
- CLLS N/A
- ALDX N/A
- EPS
- CLLS N/A
- ALDX N/A
- Revenue
- CLLS $54,747,000.00
- ALDX N/A
- Revenue This Year
- CLLS $48.52
- ALDX N/A
- Revenue Next Year
- CLLS $5.17
- ALDX N/A
- P/E Ratio
- CLLS N/A
- ALDX N/A
- Revenue Growth
- CLLS 351.26
- ALDX N/A
- 52 Week Low
- CLLS $1.10
- ALDX $1.14
- 52 Week High
- CLLS $2.78
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- CLLS 51.15
- ALDX 38.13
- Support Level
- CLLS $1.46
- ALDX $2.15
- Resistance Level
- CLLS $1.60
- ALDX $2.30
- Average True Range (ATR)
- CLLS 0.08
- ALDX 0.15
- MACD
- CLLS -0.01
- ALDX 0.06
- Stochastic Oscillator
- CLLS 52.17
- ALDX 31.03
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.